Canada markets closed
  • S&P/TSX

    20,741.75
    +197.64 (+0.96%)
     
  • S&P 500

    4,431.85
    +105.34 (+2.43%)
     
  • DOW

    34,725.47
    +564.69 (+1.65%)
     
  • CAD/USD

    0.7833
    -0.0019 (-0.24%)
     
  • CRUDE OIL

    87.29
    +0.68 (+0.79%)
     
  • BTC-CAD

    48,150.87
    +318.11 (+0.67%)
     
  • CMC Crypto 200

    863.83
    +21.37 (+2.54%)
     
  • GOLD FUTURES

    1,792.30
    -2.70 (-0.15%)
     
  • RUSSELL 2000

    1,968.51
    +37.22 (+1.93%)
     
  • 10-Yr Bond

    1.7820
    -0.0250 (-1.38%)
     
  • NASDAQ

    13,770.57
    +417.79 (+3.13%)
     
  • VOLATILITY

    27.66
    -2.83 (-9.28%)
     
  • FTSE

    7,466.07
    -88.24 (-1.17%)
     
  • NIKKEI 225

    26,717.34
    +547.04 (+2.09%)
     
  • CAD/EUR

    0.7022
    -0.0020 (-0.28%)
     

U.S. administers 468.5 million doses of COVID-19 vaccines- CDC

·1 min read
Syringes with a dose of the COVID-19 vaccine are ready for injections in Chelsea, Massachusetts

(Reuters) - The United States had administered 468,516,782 doses of COVID-19 vaccines in the country as of Saturday morning and distributed 581,107,805 doses, the U.S. Centers for Disease Control and Prevention said.

Those figures are up from the 466,348,132 vaccine doses the CDC said had gone into arms by Dec. 3 out of 580,893,145 doses delivered.

The agency said 235,297,964 people had received at least one dose, while 198,592,167 people had been fully vaccinated as of 6:00 a.m. ET on Saturday.

The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech,, as well as Johnson & Johnson's one-shot vaccine.

About 45.3 million people have received a booster dose of either Pfizer, Moderna or Johnson & Johnson's COVID-19 vaccine. Booster doses from Moderna and Johnson & Johnson were authorized by the U.S. health regulator on Oct. 20.

(Reporting by Juby Babu in Bengaluru; Editing by Daniel Wallis)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting